The Fund may be susceptible to an increased risk of loss, including losses due to adverse events that affect the Funds investments more than the market as a whole, to the extent that the Funds investments are concentrated in the securities and/or other assets of a particular issuer or issuers, country, group of countries, region, market, industry, group of industries, sector, market segment or asset class
Additional information Note This work is published under the standard license to publish agreement
For drugs like Stelara (ustekinumab, Johnson & Johnson), which faced biosimilar entry beginning in 2023 in the U.S., and Eylea (aflibercept, Regeneron), where biosimilar entry occurred in 2024, the Humira retention data provides a more accurate revenue tail model than historical small molecule LOE curves
Mechanical overload and energy storage demand: High-repetition loading (running, jumping) stresses the tendons spring-like function